Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of betamethasone and simvastatin represents a therapeutic approach that has been studied for treating psoriasis. This combination involves using topical betamethasone (a corticosteroid) alongside oral simvastatin (a statin medication). ## Therapeutic Use and Efficacy Research has demonstrated that adding oral simvastatin to topical betamethasone treatment produces a significantly enhanced therapeutic effect against psoriasis compared to topical betamethasone alone. In a double-blind, randomized, placebo-controlled study, patients who received oral simvastatin (40 mg/day) plus topical betamethasone showed a more significant decrease in Psoriasis Area and Severity Index (PASI) scores compared to those who received placebo plus topical betamethasone[1][2]. The combination appears to be well-tolerated, with no reported side effects or laboratory abnormalities in the study participants[1]. ## Mechanism of Action The enhanced efficacy of this combination likely stems from the complementary mechanisms of both drugs: - **Betamethasone**: As a corticosteroid, it provides anti-inflammatory and immunosuppressive effects, helping to reduce the inflammation associated with psoriasis. - **Simvastatin**: Beyond its cholesterol-lowering properties, simvastatin offers immunomodulatory effects that may help address the immune dysregulation in psoriasis. Statins have been recognized for their ability to scavenge free radicals and modulate immune functions[2]. ## Additional Benefits The combination may offer additional cardiovascular protection for psoriasis patients, who have an increased risk of cardiovascular events. The protective effect of statins against cardiovascular disease provides an additional rationale for using this combination[1]. Similar combination approaches have also been studied for other dermatological conditions, such as vitiligo, where betamethasone valerate 0.1% cream combined with oral simvastatin has shown promising results compared to betamethasone alone[6]. This combination represents an innovative approach to treating inflammatory skin conditions by leveraging the complementary mechanisms of a topical corticosteroid and an oral statin medication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Betamethasone and Simvastatin Combination.